Pharmacology
Conference Coverage
Durable responses with anti-BCMA CAR T-cell for multiple myeloma
Seventy-two percent of patients with relapsed/refractory multiple myeloma had ongoing responses at the time of data cutoff in the CARTITUDE-1...
Conference Coverage
ZUMA-5: Axi-cel yields high response rate in indolent NHL
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...
News
Colchicine a case study for what’s wrong with U.S. drug pricing
A Medicare/Medicaid analysis shows a prolonged public-spending burden, despite generics available outside the U.S. for pennies a pill. Meanwhile,...
Conference Coverage
The case for anti–IL-17 agents as first-line biologics in psoriatic arthritis
“The guidelines don’t give full credit to the anti–IL-17 agents.”
News
Black patients with ES-SCLC get less chemo but have better survival
Conference Coverage
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest...
News
FDA expands Xofluza indication to include postexposure flu prophylaxis
Conference Coverage
Metformin improves most outcomes for T2D during pregnancy
But the drug was associated with an increased risk of small-for-gestational-age babies.
Conference Coverage
Neoadjuvant immunotherapy combo produces high response rate in melanoma
Conference Coverage
Finerenone’s heart benefits hold up in T2D patients without CVD
In the FIDELIO-DKD trial, cardiovascular benefits from a nonsteroidal mineralocorticoid antagonist held, regardless of CVD history, in T2D...